|1.||Gribar, John J: 1 article (07/2002)|
|2.||Kimchi-Sarfaty, Chava: 1 article (07/2002)|
|3.||Gottesman, Michael M: 1 article (07/2002)|
|4.||Dietel, M: 1 article (11/2000)|
|5.||Lage, H: 1 article (11/2000)|
|1.||Breast Neoplasms (Breast Cancer)
03/01/1983 - "We believe that Bisantrene may ultimately have a major role in the effective treatment of metastatic breast cancer, and further clinical trials are warranted."
10/01/1985 - "A phase II study of bisantrene in advanced refractory breast cancer. "
01/01/1984 - "Trials conducted in patients with minimal prior treatment and with bisantrene administered via central line appear warranted for definitive assessment of the activity of this agent in breast cancer."
10/01/1986 - "Evaluation of bisantrene administered by 72-hour infusion in women with metastatic breast cancer."
01/01/1986 - "Schedule dependency of bisantrene was evaluated in refractory metastatic breast cancer. "
|2.||Melanoma (Melanoma, Malignant)
01/01/1991 - "Sixteen patients with metastatic melanoma entered this phase II study of the efficacy of monthly cycles of Bisantrene. "
01/01/1987 - "Patients with a pathologically proven diagnosis of malignant melanoma were entered into a phase II trial of bisantrene. "
08/01/1986 - "Phase II trial of bisantrene in patients with metastatic melanoma."
01/01/1987 - "We conclude that bisantrene is ineffective in the treatment of metastatic melanoma."
01/01/1987 - "Phase II evaluation of bisantrene hydrochloride in refractory malignant melanoma. "
|3.||Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
06/01/1985 - "A phase I study of bisantrene using a daily injection for 5 days was undertaken in adult patients with relapsing acute nonlymphoblastic leukemia. "
06/01/1985 - "Phase I study of bisantrene in acute nonlymphoblastic leukemia."
02/01/1993 - "Bisantrene in relapsed and refractory acute myelogenous leukemia."
11/01/1989 - "Phase II study of bisantrene in relapsed/refractory acute non lymphoid leukemias (ANLL)."
11/01/1990 - "Bisantrene proved effective in 12 out of 15 ANLL cases, inhibiting blast colony growth (50% at 1 micrograms/ml; nearly 100% at 10 micrograms/ml) in a dose-dependent, time-independent way. "
01/01/1986 - "Nevertheless, we conclude that bisantrene is not an addition to the small list of drugs useful in the management of gastric adenocarcinoma."
01/01/1988 - "Phase II study of bisantrene administered by continuous 72-hour infusion for advanced pancreatic adenocarcinoma."
01/01/1986 - "Bisantrene hydrochloride in gastric adenocarcinoma: a Southwest Oncology Group Study."
01/01/1988 - "When administered by the method we used, bisantrene cannot be recommended for treatment of advanced pancreatic adenocarcinoma."
01/01/1988 - "Eighteen ambulatory patients who had proven metastatic adenocarcinoma of the pancreas and measurable disease but no previous chemotherapy were treated with bisantrene given by constant central intravenous infusion over 72 hours at a total dose of 300 mg/m2 repeated every 3 to 4 weeks. "
01/01/1988 - "The data indicate that bisantrene, at the doses and schedule used in this study, has limited antitumor activity in pretreated children with cancer."
01/01/1988 - "Phase I/II study of bisantrene in childhood cancer: a report from the Childrens Cancer Study Group."
01/01/1986 - "Fourteen patients with pediatric malignant solid tumors, median age 15 years, received 22 courses of bisantrene in a Phase I study. "
01/01/1986 - "Phase I clinical and pharmacokinetic study of bisantrene in refractory pediatric solid tumors."
01/01/1985 - "Pathological studies of the tissues of calves sacrificed at intervals up to four weeks following rapid injection into the internal iliac artery of the same doses of Bisantrene used IV in cancer patients did not reveal evidence of extensive cytotoxicity to the infused organs."
|1.||Dihydrotachysterol (AT 10)
|5.||DNA (Deoxyribonucleic Acid)
|7.||A-Form DNA (A-DNA)
|8.||RNA (Ribonucleic Acid)
|1.||Drug Therapy (Chemotherapy)
|4.||Bone Marrow Transplantation (Transplantation, Bone Marrow)